NewLink Genetics Corporation (NASDAQ: NLNK) is one of 153 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare NewLink Genetics Corporation to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.
This is a summary of current ratings and price targets for NewLink Genetics Corporation and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|NewLink Genetics Corporation||0||0||6||0||3.00|
|NewLink Genetics Corporation Competitors||429||2081||5702||106||2.66|
NewLink Genetics Corporation currently has a consensus price target of $25.67, suggesting a potential upside of 167.08%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.10%. Given NewLink Genetics Corporation’s stronger consensus rating and higher possible upside, equities analysts plainly believe NewLink Genetics Corporation is more favorable than its peers.
Risk and Volatility
NewLink Genetics Corporation has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, NewLink Genetics Corporation’s peers have a beta of 1.55, meaning that their average share price is 55% more volatile than the S&P 500.
Earnings and Valuation
This table compares NewLink Genetics Corporation and its peers revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|NewLink Genetics Corporation||$35.77 million||-$85.15 million||-3.94|
|NewLink Genetics Corporation Competitors||$237.20 million||-$45.35 million||-80.95|
NewLink Genetics Corporation’s peers have higher revenue and earnings than NewLink Genetics Corporation. NewLink Genetics Corporation is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares NewLink Genetics Corporation and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|NewLink Genetics Corporation||-229.19%||-63.39%||-47.83%|
|NewLink Genetics Corporation Competitors||-3,062.57%||-81.06%||-35.76%|
Insider & Institutional Ownership
45.3% of NewLink Genetics Corporation shares are owned by institutional investors. Comparatively, 47.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 13.7% of NewLink Genetics Corporation shares are owned by company insiders. Comparatively, 12.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
NewLink Genetics Corporation Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.